Push Launch

Oct 9, 2021 09:00 PDT

The Oligonucleotide Therapeutics Society’s 17th Annual Meeting was held nearly the 2nd year in a row and was the moment once again phenomenally profitable. Over 1,000 attendees all around the planet engaged in lively conversations and uncovered about groundbreaking developments in a wide variety of oligonucleotide-based mostly disciplines.

The Exceptional Disorders Session featured progress in the improvement of ASO and RNAi therapeutics to take care of scarce genetic mutations that cause ailments this kind of as ALS and Angelman Syndrome. The session also emphasized the important role of patient advocacy groups for individuals with uncommon disorders and highlighted the development of N=1 Collaborative and n-Lorem. The N=1 Collaborative’s mission is to make risk-free, individualized genetic medicines that are speedily obtainable throughout the world. n-Lorem is a non-revenue which develops and provides ASO therapeutics free for daily life to sufferers with incredibly rare genetic mutations.

Presenters shared interesting information on progress in progressive parts these types of as maximizing oligonucleotide chemistry and shipping and delivery, enabling oligos to attain additional mobile and tissue varieties, new strategies of genome enhancing, and unbelievable imaging systems that display organelles in cells or program-wide distribution of ASOs.

The amazing lifesaving apps of oligonucleotide therapeutics were shown in updates on development in Ionis’s pulmonary application, Alnylam’s Stage 1 research working with RNAi therapeutics to offer prolonged reductions in blood pressure and the development of Moderna’s Covid-19 vaccine.

This year’s award winners have been chosen for their exceptional contributions to the field, and OTS would like to congratulate Hassan Fakih, Kotaro Yoshioka, MD, PhD, and Alex Garanto, PhD.

Hassan Fakih from the Section of Chemistry, McGill College was awarded the Dr. Alan M. Gewirtz Memorial Scholarship – Graduate Learners for his function on creating and screening DNA-dependent nanocarriers to provide nucleic acid therapeutics with features that enable them to move more rapidly into scientific trials.

Kotaro Yoshioka, MD, PhD of the Division of Neurology and Neurological Science, Tokyo Health-related and Dental College, was awarded the Dr. Alan M. Gewirtz Memorial Scholarship – Postdoctoral Fellows and Junior Industrial Industry experts. He has produced unique double-stranded ASO technologies that allow highly successful supply to several tissues, including skeletal muscle groups, peripheral lymphocytes, and intestines via systemic injections, and to the mind by means of intraventricular injection.

Alex Garanto, PhD of the Radboud College Health-related Heart, was awarded the Mary Ann Liebert, Inc. publishers Younger Investigator Award. His operate focuses on the design and characterization of antisense oligonucleotides (ASOs) as a possible strategy to address inherited retinal ailments. Element of his preclinical operate in concentrating on an intronic mutation in CEP290 led to a clinical demo that is at present in section 3.

The Oligonucleotide Therapeutics Modern society thanks absolutely everyone concerned in this year’s conference for contributing to the excellent success and looks ahead to hosting an in-particular person occasion following calendar year in Montreal, Canada, from Oct. 2-5, 2022. All intrigued in attending the OTS Annual Assembly are welcome as it is open up to the two members and nonmembers.

Media Contact:

Geri Beaty
Cell phone: (619) 795-9458
Email: [email protected]

Supply: The Oligonucleotide Therapeutics Modern society